顎関節症症型別Amfenac Sodium(Fenazox)とEthyl Loflazepate(Meilax)の併用効果について

  • 坂本 一郎
    東京医科歯科大学歯学部口腔外科学第二講座
  • 依田 哲也
    東京医科歯科大学歯学部口腔外科学第二講座
  • 塚原 宏泰
    東京医科歯科大学歯学部口腔外科学第二講座
  • 森田 伸
    東京医科歯科大学歯学部口腔外科学第二講座
  • 小幡 宏一
    東京医科歯科大学歯学部口腔外科学第二講座
  • 榎本 昭二
    東京医科歯科大学歯学部口腔外科学第二講座

書誌事項

タイトル別名
  • Clinical evaluation of combined treatment with amfenac sodium(Fenazox) and ethyl loflazepate(Meilax) according to the type of temporomandibular disorder.

この論文をさがす

抄録

The efficacy of combined treatment with amfenac sodium (150 mg/day for 14 days) and ethyl loflazepate (2 mg/day for 14 days) was clinically evaluated in 44 patients with temporomandibular disorders in comparison with 77 patients with temporomandibular disorders who were given amfenac sodium (150 mg/day for 14 days) alone.<BR>The 121 temporomandibular disorder patients were classified into four types (I-IV) according to the criteria proposed by the Japanese Society for the Temporomandibular Joint.<BR>The usefulness of combined treatment with amfenac sodium and ethyl loflazepate was excellent in 14 cases (31.8%), good in 14 cases (31.8%), and fair in 12 cases (27.3%).<BR>The usefulness of amfenac sodium alone was excellent in 6 cases (7.8%), good in 34 cases (44.1%), and fair in 31 cases (40.3%).

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (21)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ